Stryker Corporation $SYK Shares Purchased by Linscomb Wealth Inc.

Linscomb Wealth Inc. boosted its stake in Stryker Corporation (NYSE:SYK) by 2.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 16,340 shares of the medical technology company’s stock after acquiring an additional 456 shares during the quarter. Linscomb Wealth Inc.’s holdings in Stryker were worth $6,465,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. AMG National Trust Bank grew its stake in Stryker by 0.8% in the 2nd quarter. AMG National Trust Bank now owns 15,695 shares of the medical technology company’s stock valued at $6,209,000 after acquiring an additional 122 shares during the period. Creekmur Asset Management LLC grew its stake in Stryker by 40.6% in the 2nd quarter. Creekmur Asset Management LLC now owns 841 shares of the medical technology company’s stock valued at $333,000 after acquiring an additional 243 shares during the period. Kovack Advisors Inc. grew its stake in Stryker by 3.6% in the 2nd quarter. Kovack Advisors Inc. now owns 771 shares of the medical technology company’s stock valued at $305,000 after acquiring an additional 27 shares during the period. IFG Advisory LLC grew its stake in Stryker by 1.6% in the 2nd quarter. IFG Advisory LLC now owns 3,011 shares of the medical technology company’s stock valued at $1,191,000 after acquiring an additional 48 shares during the period. Finally, Mesirow Financial Investment Management Inc. grew its stake in Stryker by 286.4% in the 2nd quarter. Mesirow Financial Investment Management Inc. now owns 58,670 shares of the medical technology company’s stock valued at $23,215,000 after acquiring an additional 43,487 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 0.1%

NYSE SYK opened at $369.31 on Friday. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The business’s fifty day simple moving average is $378.83 and its 200-day simple moving average is $380.54. The firm has a market cap of $141.19 billion, a PE ratio of 48.92, a P/E/G ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the previous year, the firm earned $2.87 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SYK. Truist Financial dropped their price target on shares of Stryker from $415.00 to $407.00 and set a “hold” rating on the stock in a research note on Wednesday, October 15th. Needham & Company LLC raised their price objective on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Barclays raised their price objective on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Wells Fargo & Company raised their price objective on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Finally, Redburn Partners set a $420.00 price objective on Stryker in a report on Thursday, September 18th. Thirteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $434.32.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 5.90% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.